Evidence map›Paper›PMID 36497175›Full record

ArticleCells2022

CHRDL1 Regulates Stemness in Glioma Stem-like Cells.

Inka Berglar, Stephanie Hehlgans, Andrej Wehle, Caterina Roth, Christel Herold-Mende, Franz Rödel, Donat Kögel, Benedikt Linder

Abstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. BRAT1 - a new therapeutic target for glioblastoma.Cellular and molecular life sciences : CMLS · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Inka BerglarExperimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-1115-6081
Stephanie HehlgansDepartment of Radiotherapy and Oncology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-6816-3450
Andrej WehleExperimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-6594-709X
Caterina RothExperimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-7998-8837
Christel Herold-MendeDivision of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, INF400, 69120 Heidelberg, Germany.ORCID 0000-0002-1915-745X
Franz RödelDepartment of Radiotherapy and Oncology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0001-6057-1022
Donat KögelExperimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0003-1209-0210
Benedikt LinderExperimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.ORCID 0000-0003-0908-571X

Funding

Deutsche Forschungsgemeinschaft LI 3687/2-1
6 · The paper itself

Abstract

Glioblastoma (GBM) still presents as one of the most aggressive tumours in the brain, which despite enormous research efforts, remains incurable today. As many theories evolve around the persistent recurrence of this malignancy, the assumption of a small population of cells with a stem-like phenotype remains a key driver of its infiltrative nature. In this article, we research Chordin-like 1 (CHRDL1), a secreted protein, as a potential key regulator of the glioma stem-like cell (GSC) phenotype. It has been shown that CHRDL1 antagonizes the function of bone morphogenic protein 4 (BMP4), which induces GSC differentiation and, hence, reduces tumorigenicity. We, therefore, employed two previously described GSCs spheroid cultures and depleted them of CHRDL1 using the stable transduction of a CHRDL1-targeting shRNA. We show with in vitro cell-based assays (MTT, limiting dilution, and sphere formation assays), Western blots, irradiation procedures, and quantitative real-time PCR that the depletion of the secreted BMP4 antagonist CHRDL1 prominently decreases functional and molecular stemness traits resulting in enhanced radiation sensitivity. As a result, we postulate CHRDL1 as an enforcer of stemness in GSCs and find additional evidence that high CHRDL1 expression might also serve as a marker protein to determine BMP4 susceptibility.

Indexed as

GlioblastomaGliomaCell Line, TumorHumansNeoplastic Stem CellsBMP4CHRDL1glioblastomagliomaglioma stem-like cells

Identifiers

PMID36497175
PMCPMC9741078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.